CD3xCD19 – Talk Bio

Actionable Insights Powered by AI

Merck Acquires Clinical-Stage CD3xCD19 Bispecific Antibody for $700M

Merck, CD3xCD19 bispecific antibody, Curon Biopharmaceutical, clinical-stage, pharmaceutical acquisition